Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Charlotte Soderman"'
Autor:
Charlotte Soderman, Mark Clements, Pär Myrelid, Agnieszka Wagner, David Andersson, Hans Strid, Anders Forss, Fredrik Hjelm, Jonas F. Ludvigsson, Jonas Halfvarson, Ola Olén
Publikováno v:
Scandinavian Journal of Gastroenterology. 56:680-686
Background Prospectively and systematically collected real-world data on the effectiveness of ustekinumab (anti-interleukin-12/23) for treating Crohns disease (CD) are still limited. Aim To assess the short-term real-world effectiveness of ustekinuma
Autor:
Silvio Danese, Severine Vermeire, Geert D'Haens, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Laurent Peyrin-Biroulet, Rodolfo Rocca, Susana Lopes, Flavio Caprioli, Sandro Ardizzone, Ana Echarri Piudo, Paolo Gionchetti, Xavier Roblin, Ursula Seidler, David Andersson, Kamal Patel, Pierre Desreumaux, Simone Saibeni, Gustav From, Miroslav Fedurco, Milos Gregus, Yoram Bouhnik, Andreas Luegering, Rocco Cosintino, Ivan Bunganic, Jaime Ramos, Mariam Aguas Peris, Olivier Dewit, Mariabeatrice Principi, Emma Wesley, Paula Lago, Stephane Nancey, María Dolores Martín Arranz, Pieter Hindryckx, Ambrogio Orlando, Andrea Geccherle, Maria Laura Annunziata, Bu'hussain Hayee, Jozef Balaz, Francisco Portela, Cyrielle Gilletta, Torsten Kucharzik, Miguel Mínguez, Javier Pérez Gisbert, Ana Gutiérrez Casbas, Edouard Louis, Marco Marino, Gareth Parkes, Fraser Cummings, Bindia Jharap, Jens Kjeldsen, Luís Correia, Paula Ministro, Matthias Ebert, Erik Hertervig, Dirk Staessen, Joris Dutré, Arnaud Colard, Graham Morrison, Henning Glerup, Jens Frederik Dahlerup, Frank Wolfhagen, Marian Batovsky, Martin Molnar, Barbora Kadleckova, Paulo Caldeira, David Laharie, Xavier Hebuterne, Bruno Bonaz, Matthieu Allez, Andreas Fischer, Joaquín Ernesto Hinojosa Del Val, Miriam Mañosa Ciria, Jose Manuel Herrera Justiniano, Charlotte Soderman, Rajiv Chandy, Craig Mowat, Peter Irving, Jan Fallingborg, Jan Matous, Tomas Douda, Romain Altwegg, Jose Manuel Benitez, María Teresa Arroyo Villarino, Jordi Guardiola Capón, Daniel Ginard Vicenc, Pieter Dewint, Sven Almer, Sebastien Kindt
Publikováno v:
Danese, S, Vermeire, S, D'Haens, G, Panés, J, Dignass, A, Magro, F, Nazar, M, Le Bars, M, Lahaye, M, Ni, L, Bravata, I, Lavie, F, Daperno, M, Lukáš, M, Armuzzi, A, Löwenberg, M, Gaya, D R, Peyrin-Biroulet, L & STARDUST study group 2022, ' Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 4, pp. 294-306 . https://doi.org/10.1016/S2468-1253(21)00474-X
lancet. Gastroenterology & hepatology, 7(4), 294-306. Elsevier Limited
The Lancet Gastroenterology and Hepatology, 7(4), 294-306. Elsevier Ltd
lancet. Gastroenterology & hepatology, 7(4), 294-306. Elsevier Limited
The Lancet Gastroenterology and Hepatology, 7(4), 294-306. Elsevier Ltd
Background: A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c41ea76bc7f88c535499cddcf9ba8ad
https://pure.au.dk/portal/da/publications/treat-to-target-versus-standard-of-care-for-patients-with-crohns-disease-treated-with-ustekinumab-stardust(6e02a521-a146-4afb-857c-d91bbe745a10).html
https://pure.au.dk/portal/da/publications/treat-to-target-versus-standard-of-care-for-patients-with-crohns-disease-treated-with-ustekinumab-stardust(6e02a521-a146-4afb-857c-d91bbe745a10).html
Autor:
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents. Objectives: To provide real-world data in unselected patients with Crohn’s disease (CD), treated with ustekinum
Externí odkaz:
https://doaj.org/article/22237179ddef46c3851d7e3572f2060b
Autor:
Mats Sjöberg, Per Karlén, Jenny Delin, Sven Almer, Hans Strid, Sara Rundquist, Charlotte Soderman, David Öberg, C. Malmgren, Ruzan Udumyan, Daniel Bergemalm, Erik Hertervig, Jonas Halfvarson, Jenny Gunnarsson, Carl Eriksson, Henrik Hjortswang, Olof Grip, Vyron Lykiardopoulos
Publikováno v:
Journal of Crohn's and Colitis. 14:S576-S577
Background Clinical trials may not readily reflect clinical practice. We aimed to assess the clinical effectiveness of vedolizumab in a real-world cohort of patients with ulcerative colitis (UC). Methods This is a prospective, observational, multi-ce
Autor:
David Öberg, Carl Eriksson, Olof Grip, Sara Rundquist, Charlotte Soderman, Sven Almer, C. Malmgren, Hans Strid, Vyron Lykiardopoulos, Erik Hertervig, Ruzan Udumyan, Henrik Hjortswang, Mats Sjöberg, Jenny Delin, Jonas Halfvarson, Jan Marsal, Per Karlén, Daniel Bergemalm, Jenny Gunnarsson
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology
Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD). Methods: This study was a prospective, obser
Publikováno v:
Gastroenterology. 158:S-1474
Autor:
Mats Sjöberg, Jenny Delin, Carl Eriksson, Bergemalm Daniel, Hans Strid, Ruzan Udumyan, Jenny Gunnarsson, Byron Lykiardopoulos, Sara Rundquist, Per Karlén, Charlotte Soderman, Henrik Hjortswang, Jonas Halfvarson, C. Malmgren, Erik Hertervig, Sven Almer, Olof Grip, David Öberg
Publikováno v:
Gastroenterology. 158:S-963
Autor:
Michael Eberhardson, Mari Thörn, Pär Myrelid, Erik Hertervig, Daniel Bergemalm, Per Karlén, Lina Vigren, Charlotte Soderman, Jonas F. Ludvigsson, Jan Björk, Yang Cao, Hans Strid, Pontus Karling, Jonas Halfvarson, Sven Almer, Daniel Sjöberg, Carl Eriksson, Jan Marsal
Publikováno v:
Scandinavian journal of gastroenterology. 52(6-7)
Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long
Autor:
David Öberg, Mats Sjöberg, Daniel Bergemalm, Jenny Delin, Charlotte Soderman, Hans Strid, Vyron Lykiardopoulos, Olof Grip, Carl Eriksson, Ruzan Udumyan, Sara Rundquist, Jenny Gunnarsson, Jonas Halfvarson, Erik Hertervig, Per Karlén, Henrik Hjortswang, Sven Almer, C. Malmgren
Publikováno v:
Journal of Crohn's and Colitis. 12:S382-S383
Clinical effectiveness of vedolizumab : Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
Autor:
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). Design: A nationwide, prospective multicentre extension of
Externí odkaz:
https://doaj.org/article/520ccc3a7100409a8d39655c69ab7181